Revenue and margins are highly volatile, with gross margin oscillating between roughly -159% and 100% and operating losses persisting in most quarters despite the 3Q26 revenue rebound to $116.5M.
Xencor, Inc. (XNCR) annual income statement — 15-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 |
|---|
| Sales/Revenue | 200.49M | 125.58M | 110.49M | 174.62M | 164.58M | 275.11M | 122.69M | 156.7M | 40.6M | 35.71M | 87.52M | 27.76M | 9.52M | 10.17M | 9.52M | 6.85M |
| Revenue Growth % | 19.8% | 13.65% | -36.72% | 6.1% | -40.18% | 124.23% | -21.7% | 285.93% | 13.7% | -59.2% | 215.25% | 191.62% | -6.41% | 6.8% | 39.06% | - |
| Cost of Goods Sold | 5.14M | 10.51M | 227.69M | 0 | 199.56M | 192.51M | 169.8M | 118.59M | 97.5M | 71.77M | 51.87M | 34.14M | 18.52M | 17M | 12.67M | 0 |
| COGS % of Revenue | - | 8.37% | 206.06% | - | 121.26% | 69.97% | 138.39% | 75.68% | 240.13% | 200.98% | 59.27% | 122.97% | 194.5% | 167.13% | 133.01% | - |
| Gross Profit | 195.35M | 115.06M | -117.19M | 174.62M | -34.98M | 82.6M | -47.11M | 38.11M | -56.9M | -36.06M | 35.65M | -6.38M | -9M | -6.83M | -3.14M | 6.85M |
| Gross Margin % | 97.43% | 91.63% | -106.06% | 100% | -21.26% | 30.03% | -38.39% | 24.32% | -140.13% | -100.98% | 40.73% | -22.97% | -94.5% | -67.13% | -33.01% | 100% |
| Gross Profit Growth % | - | 198.18% | -167.12% | 599.13% | -142.35% | 275.35% | -223.61% | 166.98% | -57.78% | -201.16% | 658.92% | 29.1% | -31.75% | -117.18% | -145.9% | - |
| Operating Expenses | 341.04M | 292.57M | 61.22M | 306.98M | 47.49M | 38.84M | 29.69M | 24.29M | 119.97M | 89.27M | 64.98M | 46.1M | 25.98M | 20.69M | 15.75M | 16.3M |
| OpEx % of Revenue | - | 232.98% | 55.4% | 175.8% | 28.85% | 14.12% | 24.2% | 15.5% | 295.48% | 249.99% | 74.25% | 166.05% | 272.87% | 203.42% | 165.41% | 238.01% |
| Selling, General & Admin | 60.49M | 63.64M | 58.89M | 53.38M | 47.49M | 38.84M | 29.69M | 24.29M | 22.47M | 17.5M | 13.11M | 11.96M | 7.46M | 3.69M | 3.09M | 3.64M |
| SG&A % of Revenue | - | 50.68% | 53.29% | 30.57% | 28.85% | 14.12% | 24.2% | 15.5% | 55.35% | 49.01% | 14.98% | 43.08% | 78.37% | 36.3% | 32.4% | 53.12% |
| Research & Development | 285.69M | 239.43M | 227.69M | 253.6M | 199.56M | 192.51M | 169.8M | 118.59M | 97.5M | 71.77M | 51.87M | 34.14M | 18.52M | 17M | 12.67M | 12.66M |
| R&D % of Revenue | - | 190.67% | 206.06% | 145.23% | 121.26% | 69.97% | 138.39% | 75.68% | 240.13% | 200.98% | 59.27% | 122.97% | 194.5% | 167.13% | 133.01% | 184.89% |
| Other Operating Expenses | -2M | -10.51M | -225.36M | 0 | -199.56M | -192.51M | -169.8M | -118.59M | 8.96M | 4.17M | 2.08M | 746K | 44K | 31K | 86K | 65K |
| Operating Income | -145.69M | -177.5M | -178.41M | -132.36M | -82.47M | 43.77M | -76.8M | 13.82M | -79.37M | -53.56M | 22.54M | -18.34M | -16.46M | -10.52M | -6.23M | -9.45M |
| Operating Margin % | -72.67% | -141.35% | -161.47% | -75.8% | -50.11% | 15.91% | -62.59% | 8.82% | -195.48% | -149.99% | 25.75% | -66.05% | -172.87% | -103.42% | -65.41% | -138.01% |
| Operating Income Growth % | - | 0.51% | -34.79% | -60.49% | -288.44% | 156.99% | -655.53% | 117.42% | -48.18% | -337.63% | 222.91% | -11.43% | -56.44% | -68.86% | 34.09% | - |
| EBITDA | -135.87M | -166.99M | -166.3M | -120.86M | -73.67M | 51.26M | -71M | 18.12M | -76.12M | -51.53M | 24.01M | -17.23M | -15.57M | -9.81M | -5.7M | -8.85M |
| EBITDA Margin % | -67.77% | -132.98% | -150.51% | -69.22% | -44.77% | 18.63% | -57.87% | 11.56% | -187.47% | -144.3% | 27.43% | -62.05% | -163.6% | -96.43% | -59.88% | -129.14% |
| EBITDA Growth % | -24.77% | -0.41% | -37.59% | -64.05% | -243.73% | 172.19% | -491.81% | 123.81% | -47.71% | -314.66% | 239.37% | -10.59% | -58.78% | -72% | 35.52% | - |
| D&A (Non-Cash Add-back) | 9.82M | 10.51M | 12.11M | 11.5M | 8.8M | 7.49M | 5.79M | 4.3M | 3.25M | 2.03M | 1.47M | 1.11M | 882K | 711K | 527K | 607K |
| EBIT | -92.04M | -57.49M | -198.28M | -113.46M | -54.49M | 82.64M | -76.8M | 13.82M | -79.37M | -42.73M | 46.14M | -17.58M | -16.41M | -59.05M | -6.13M | -9.35M |
| Net Interest Income | -2.16M | -4.4M | -4.71M | 18.63M | 4.82M | 849K | 7.26M | 13.62M | 9.09M | 4.18M | 2.07M | 731K | 24K | -1.2M | -2.45M | -1.82M |
| Interest Income | 21.36M | 27.52M | 31.93M | 18.63M | 4.82M | 862K | 7.26M | 13.62M | 9.1M | 4.19M | 2.09M | 744K | 33K | 14K | 11K | 34K |
| Interest Expense | 23.52M | 31.93M | 36.64M | 0 | 0 | 13K | 0 | 0 | 16K | 13K | 21K | 13K | 9K | 1.21M | 2.46M | 1.85M |
| Other Income/Expense | 30.13M | 87.87M | -56.52M | 12.73M | 27.96M | 38.86M | 7.46M | 13.36M | 8.96M | 4.17M | 2.08M | 746K | 35K | -49.74M | -2.36M | -1.75M |
| Pretax Income | -115.56M | -89.42M | -234.92M | -119.63M | -54.51M | 82.63M | -69.33M | 27.19M | -70.41M | -49.39M | 24.62M | -17.59M | -16.42M | -60.26M | -8.59M | -11.2M |
| Pretax Margin % | -57.64% | -71.21% | -212.61% | -68.51% | -33.12% | 30.04% | -56.51% | 17.35% | -173.41% | -138.3% | 28.13% | -63.37% | -172.5% | -592.39% | -90.24% | -163.57% |
| Income Tax | 2.3M | 2.5M | 1.62M | 13.66M | 673K | 0 | 0 | 312K | 0 | -463K | 991K | 0 | 0 | 533K | 0 | 0 |
| Effective Tax Rate % | -1.99% | -2.8% | -0.69% | -11.42% | -1.23% | 0% | 0% | 1.15% | 0% | 0.94% | 4.03% | 0% | 0% | -0.88% | 0% | 0% |
| Net Income | -117.86M | -91.92M | -232.62M | -133.13M | -55.18M | 82.63M | -69.33M | 26.88M | -70.41M | -48.92M | 23.63M | -17.59M | -16.42M | -60.26M | -8.59M | -11.2M |
| Net Margin % | -58.79% | -73.2% | -210.53% | -76.24% | -33.53% | 30.04% | -56.51% | 17.15% | -173.41% | -137% | 26.99% | -63.37% | -172.5% | -592.39% | -90.24% | -163.57% |
| Net Income Growth % | 15.05% | 60.48% | -74.73% | -141.27% | -166.78% | 219.18% | -357.98% | 138.17% | -43.91% | -307.09% | 234.29% | -7.12% | 72.75% | -601.16% | 23.29% | - |
| Net Income (Continuing) | -117.86M | -91.92M | -236.54M | -133.3M | -55.18M | 82.63M | -69.33M | 26.88M | -70.41M | -38.49M | 45.13M | -17.59M | -16.42M | -60.26M | -8.59M | -11.2M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | -3.58M | 337K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.50 | -1.24 | -3.58 | -2.08 | -0.93 | 1.37 | -1.11 | 0.46 | -1.31 | -1.05 | 0.56 | -0.45 | -0.52 | -1.92 | -0.51 | -0.67 |
| EPS Growth % | 15.43% | 65.36% | -72.12% | -123.66% | -167.88% | 223.42% | -341.3% | 135.11% | -24.76% | -287.5% | 224.44% | 13.46% | 72.92% | -276.47% | 23.88% | - |
| EPS (Basic) | - | -1.24 | -3.58 | -2.08 | -0.93 | 1.42 | -1.11 | 0.48 | -1.31 | -1.05 | 0.57 | -0.45 | -0.52 | -1.92 | -0.51 | -0.67 |
| Diluted Shares Outstanding | 78.35M | 74.24M | 65.04M | 60.5M | 59.65M | 60.5M | 57.21M | 58.47M | 53.94M | 46.82M | 42.39M | 39.02M | 31.43M | 31.35M | 16.69M | 16.69M |
| Basic Shares Outstanding | 76.22M | 74.24M | 65.04M | 60.5M | 59.65M | 58.38M | 57.21M | 56.53M | 53.75M | 46.82M | 41.27M | 39.02M | 31.39M | 31.35M | 16.69M | 16.69M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quick answers to the most common questions about buying XNCR stock.
For fiscal year 2025, Xencor, Inc. (XNCR) reported total revenue of $125.6M. This represents a 1733.5% increase compared to $6.8M in 2011.
Xencor, Inc. (XNCR) reported a net loss of $91.9M for the fiscal year ending 2025.
Xencor, Inc. (XNCR) reported an operating income of $-177.5M, resulting in an operating profit margin of -141.4%. This margin reflects the operational efficiency of the business before interest and taxes.
Xencor, Inc. (XNCR) generated $115.1M in gross profit for the year, representing a gross profit margin of 91.6%. This demonstrates the company's core pricing power and production efficiency.
Key Metrics
Top Statement Risk
Lumpy collaboration revenue dependence
Metrics are mathematically derived from official filings.
Lumpy Collaboration Revenue Drives Volatility
Based on the reported quarterly figures, Xencor's revenue swung from $70.0M in 4Q24 to $4.5M in 1Q26 and then rebounded to $116.5M in 3Q26, indicating growth driven by irregular milestone and upfront payments rather than steady royalty expansion.
The quarterly series suggests that top-line movements reflect the timing of partner-controlled events rather than a consistent underlying growth rate. The 3Q26 spike appears to be a discrete collaboration recognition event, which may not be repeatable and warrants investigation before extrapolating the trend. Investors should monitor whether royalty revenue alone can sustain the cost base over successive quarters.
Gross Margin Reflects Royalty Mix Shifts
The reported gross margin oscillated between roughly -159% and 100% over the period, with the 3Q25 negative figure of -158.9% coinciding with a $54.4M cost line that the data appears to classify as cost of revenue.
Gross margin behavior appears to reflect the timing of collaboration cost recognition rather than a structural pricing or cost shift. Quarters with zero reported COGS produce 100% margins, which suggests the metric is highly sensitive to classification rather than operating efficiency. The reported gross margin should therefore be interpreted cautiously and not as a stable indicator of pricing power.
Operating Losses Persist Despite Revenue Gains
Based on the reported TTM figures, operating margin stands at -141.4%, and R&D spending of $84.3M in 3Q26 against $9.4M of SG&A indicates that cost growth remains concentrated in clinical development.
The R&D-to-SG&A ratio points to a high fixed-cost base dominated by clinical execution, which limits operating leverage even when revenue rises. Operating income turned positive only in 3Q26 at $22.9M, a single quarter whose durability remains unproven. Investors should monitor whether R&D intensity moderates as internal late-stage programs advance.
Net Income Dependent on Non-Operating Items
Reported net income of $39.4M in 3Q26 exceeded operating income of $22.9M, while EPS of $0.50 and a 33.8% net margin appear inconsistent with the -141.4% TTM operating margin, suggesting non-operating or one-time gains.
The gap between operating and net income in 3Q26 suggests material non-operating contributions, potentially including interest income or other gains not evident in the operating line. Stock-based compensation of roughly $9M to $19M per quarter is material relative to reported losses and may distort underlying earnings quality. The reconciliation of these items warrants further investigation before the 3Q26 profit is treated as a run-rate.
Sustained Losses Challenge Platform Thesis
Persistent quarterly losses across most of the ten-quarter window, with net losses of $128.9M in 1Q26 and cumulative R&D above $60M per quarter, raise the question of whether royalty and collaboration income can fund the pipeline without further capital.
A bearish reading would emphasize that profitable quarters appear episodic and tied to partner events, while R&D commitments remain structurally elevated. If collaboration payments slow, the reported cost base suggests cash consumption could accelerate, potentially requiring dilutive financing. The absence of current cash and runway data in the supplied information limits how firmly this risk can be sized.